Terms: = Sarcomas AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras AND Treatment
72 results:
1. The diagnosis and treatment for primary cardiac angiosarcoma with n-ras gene mutation and MSI-L: A case report and review of the literature.
Sun J; Wei T; Sun B; Su J; Liu H; Wang D; Li X
Medicine (Baltimore); 2023 Dec; 102(51):e36682. PubMed ID: 38134104
[TBL] [Abstract] [Full Text] [Related]
2. Mutant hras Signaling and Rationale for Use of Farnesyltransferase Inhibitors in Head and Neck Squamous Cell Carcinoma.
Wang J; Al-Majid D; Brenner JC; Smith JD
Target Oncol; 2023 Sep; 18(5):643-655. PubMed ID: 37665491
[TBL] [Abstract] [Full Text] [Related]
3. Small molecular inhibitors for KRAS-mutant cancers.
Wu X; Song W; Cheng C; Liu Z; Li X; Cui Y; Gao Y; Li D
Front Immunol; 2023; 14():1223433. PubMed ID: 37662925
[TBL] [Abstract] [Full Text] [Related]
4. KRAS Pathways: A Potential Gateway for Cancer Therapeutics and Diagnostics.
Tripathi PK; Mittal KR; Jain N; Sharma N; Jain CK
Recent Pat Anticancer Drug Discov; 2024; 19(3):268-279. PubMed ID: 37038676
[TBL] [Abstract] [Full Text] [Related]
5. Targeting Harvey rat sarcoma viral oncogene homolog in head and neck cancer: how to move forward?
Ben Yahia H; Petit FM; Saada-Bouzid E
Curr Opin Oncol; 2023 May; 35(3):178-185. PubMed ID: 36966498
[TBL] [Abstract] [Full Text] [Related]
6. hras overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors.
Liverani C; Spadazzi C; Ibrahim T; Pieri F; Foca F; Calabrese C; De Vita A; Miserocchi G; Cocchi C; Vanni S; Ercolani G; Cavaliere D; Ranallo N; Chiadini E; Prisinzano G; Severi S; Sansovini M; Martinelli G; Bongiovanni A; Mercatali L
Front Endocrinol (Lausanne); 2022; 13():1045038. PubMed ID: 36743926
[TBL] [Abstract] [Full Text] [Related]
7. Targeting farnesylation as a novel therapeutic approach in hras-mutant rhabdomyosarcoma.
Odeniyide P; Yohe ME; Pollard K; Vaseva AV; Calizo A; Zhang L; Rodriguez FJ; Gross JM; Allen AN; Wan X; Somwar R; Schreck KC; Kessler L; Wang J; Pratilas CA
Oncogene; 2022 May; 41(21):2973-2983. PubMed ID: 35459782
[TBL] [Abstract] [Full Text] [Related]
8. Morbidity and long-term results in patients with wild and mutant type Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations undergoing colorectal cancer surgery.
Aziret M; Subasi O; Bilir C; Tozlu M; Altıntoprak F; Karaman K; Ercan M; Celebi F
Ann Ital Chir; 2022; 92():65-77. PubMed ID: 35342104
[TBL] [Abstract] [Full Text] [Related]
9. k-ras and p53 mouse model with molecular characteristics of human rhabdomyosarcoma and translational applications.
Nakahata K; Simons BW; Pozzo E; Shuck R; Kurenbekova L; Prudowsky Z; Dholakia K; Coarfa C; Patel TD; Donehower LA; Yustein JT
Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35174853
[TBL] [Abstract] [Full Text] [Related]
10. KRAS Oncogene Mutations in Colorectal Cancer Patients in a Nepalese Tertiary Care Hospital.
Basnet BK; Gautam B; Ranabhat K; Paudel BD; Chapagain Acharya S; Bastola SR; Gyawali B
J Nepal Health Res Counc; 2021 Dec; 19(3):504-507. PubMed ID: 35140422
[TBL] [Abstract] [Full Text] [Related]
11. Primary breast sarcoma: A case series.
Ahuja M; Mallya V; Mandal S; Tomar R; Aggarwal R; Khurana N; Lal P
Indian J Pathol Microbiol; 2022; 65(1):152-156. PubMed ID: 35074983
[TBL] [Abstract] [Full Text] [Related]
12. Sesamol induces cytotoxicity via mitochondrial apoptosis in SCC-25 cells.
Ezhilarasan D; Ali D; Varghese R
Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S423-S433. PubMed ID: 34586880
[TBL] [Abstract] [Full Text] [Related]
13. The utility of the Ion Torrent PGM next generation sequencing for analysis of the most commonly mutated genes among patients with colorectal cancer in India.
Mehra S; Tiwari AK; Mehta SP; Sachdev R; Rajvanshi C; Chauhan R; Saini A; Vaid A
Indian J Cancer; 2022; 59(2):218-222. PubMed ID: 33753628
[TBL] [Abstract] [Full Text] [Related]
14. Inhibiting the "Undruggable" RAS/Farnesyltransferase (FTase) Cancer Target by Manumycin-related Natural Products.
Silva LR; da Silva-Júnior EF
Curr Med Chem; 2022; 29(2):189-211. PubMed ID: 33719954
[TBL] [Abstract] [Full Text] [Related]
15. The effect of microRNA-330 replacement on inhibition of growth and migration in renal cancer cells.
Liu J; Song X; Ren Z
Biotechnol Appl Biochem; 2022 Apr; 69(2):558-566. PubMed ID: 33605482
[TBL] [Abstract] [Full Text] [Related]
16. Spatiotemporal metabolic dynamics of the photosensitizer talaporfin sodium in carcinoma and sarcoma.
Saito T; Tsukahara T; Suzuki T; Nojima I; Tadano H; Kawai N; Kubo T; Hirohashi Y; Kanaseki T; Torigoe T; Li L
Cancer Sci; 2021 Feb; 112(2):550-562. PubMed ID: 33190360
[TBL] [Abstract] [Full Text] [Related]
17. Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma.
Chan JY; Lim JQ; Yeong J; Ravi V; Guan P; Boot A; Tay TKY; Selvarajan S; Md Nasir ND; Loh JH; Ong CK; Huang D; Tan J; Li Z; Ng CC; Tan TT; Masuzawa M; Sung KW; Farid M; Quek RHH; Tan NC; Teo MCC; Rozen SG; Tan P; Futreal A; Teh BT; Soo KC
J Clin Invest; 2020 Nov; 130(11):5833-5846. PubMed ID: 33016928
[TBL] [Abstract] [Full Text] [Related]
18. miR-192 enhances sensitivity of methotrexate drug to MG-63 osteosarcoma cancer cells.
Bazavar M; Fazli J; Valizadeh A; Ma B; Mohammadi E; Asemi Z; Alemi F; Maleki M; Xing S; Yousefi B
Pathol Res Pract; 2020 Nov; 216(11):153176. PubMed ID: 32861171
[TBL] [Abstract] [Full Text] [Related]
19. Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient.
Lee HW; Chung W; Lee HO; Jeong DE; Jo A; Lim JE; Hong JH; Nam DH; Jeong BC; Park SH; Joo KM; Park WY
Genome Med; 2020 May; 12(1):47. PubMed ID: 32460812
[TBL] [Abstract] [Full Text] [Related]
20. Human papillomavirus-negative epithelial proliferations resembling condylomata acuminata in a patient receiving vemurafenib for Stage IV melanoma.
Peters MA; Geukes Foppen MH; Blank CU; Crijns MB
J Cancer Res Ther; 2020; 16(1):170-172. PubMed ID: 32362631
[TBL] [Abstract] [Full Text] [Related]
[Next]
